LOX-blocking drugs for chemo-resistant triple-negative breast cancer
Developing novel LOX inhibitors to target chemotherapy resistant TNBC
['FUNDING_OTHER'] · LOXIGEN, INC. · NIH-11178114
This work is creating new drugs that block a protein called LOX to help people whose triple-negative breast cancer has stopped responding to chemotherapy.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LOXIGEN, INC. (nih funded) |
| Locations | 1 site (CHARLESTON, UNITED STATES) |
| Trial ID | NIH-11178114 on ClinicalTrials.gov |
What this research studies
Researchers are developing selective LOX inhibitors—small molecules designed to block a protein that helps tumors resist chemotherapy. They use high-throughput screening of compound libraries, then optimize hits for potency, selectivity, oral absorption, and safety. Promising candidates are tested in cell models and in mouse models of chemoresistant triple-negative breast cancer to see if they restore sensitivity to doxorubicin. The aim is to produce well-tolerated drug candidates that could move toward human testing.
Who could benefit from this research
Good fit: People with triple-negative breast cancer whose tumors no longer respond to standard chemotherapy would be the most likely candidates for trials of a LOX inhibitor.
Not a fit: People with other breast cancer subtypes, tumors that still respond to chemotherapy, or cancers driven by different resistance mechanisms may not benefit from a LOX-targeting drug.
Why it matters
Potential benefit: If successful, these drugs could restore chemotherapy sensitivity in some people with chemo-resistant triple-negative breast cancer and improve outcomes.
How similar studies have performed: Preclinical studies, including mouse models, have shown that blocking LOX can re-sensitize tumors to doxorubicin, but selective, well-tolerated LOX drugs are still new and under development.
Where this research is happening
CHARLESTON, UNITED STATES
- LOXIGEN, INC. — CHARLESTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SAHIN, OZGUR — LOXIGEN, INC.
- Study coordinator: SAHIN, OZGUR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.